

[Open Peer Review on Qeios](#)

Anti-CD19/CD20/CD22/CD30 CAR-T Cells

National Cancer Institute

Source

National Cancer Institute. *Anti-CD19/CD20/CD22/CD30 CAR-T Cells*. NCI Thesaurus. Code C151935.

A preparation of human T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19), CD20, CD22 and CD30, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD19/CD20/CD22/CD30 CAR-T cells target and bind to CD19, CD20, CD22 and CD30 expressed on the surface of certain tumor cells. This induces selective toxicity in tumor cells expressing these TAAs. The TAAs are overexpressed in certain hematologic malignancies.